Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Merck & Co. Inc., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net income (loss) from continuing operations 3,744 3,161 5,461 4,767 (1,226) 4,750 (5,972) 2,825 3,018 3,252 3,949 4,307 3,824 4,571 1,214 2,749 (2,091) 2,944 3,010 3,219
Amortization 675 633 614 473 462 562 477 543 462 460 464 699 405 360 357 514
Depreciation 522 553 518 511 502 452 426 448 430 499 474 421 430 399 371 378
Depreciation and amortization (legacy) 904 852 1,048 821
Intangible asset impairment charges 39 779 13 839 887 23 302 1,683 15 20
(Income) loss from investments in equity securities, net 155 31 (57) (143) (100) 34 176 (450) 58 370 283 708 (405) (681) (280) (574)
Charges for certain research and development asset acquisitions 700 2,100 656 10,217 1,192 1,556 2,660
Deferred income taxes (616) (401) (181) (51) (931) (336) (355) (277) (307) (661) (262) (338) 159 (1) 11 18 (715) (75) 40 82
Share-based compensation 187 195 203 176 167 164 169 145 145 139 137 120 119 117 132 111 121 125 121 108
Other (101) 437 91 83 449 (99) 202 (197) 132 393 633 143 306 171 92 236 396 (243) (345) 143
Net changes in assets and liabilities (1,855) 2,582 (1,012) (3,382) 144 2,177 (1,636) (2,890) (347) 263 (1,399) (1,299) (45) (139) (1,463) (2,192) 1,048 (1,445) (527) (3,666)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities (294) 6,130 176 (1,677) 1,472 2,967 9,676 (1,486) 1,412 2,350 353 454 1,271 226 776 (1,509) 6,097 (771) 357 (2,512)
Net cash provided by operating activities 3,450 9,291 5,637 3,090 246 7,717 3,704 1,339 4,430 5,602 4,302 4,761 5,095 4,797 1,990 1,240 4,006 2,173 3,367 707
Capital expenditures (937) (783) (791) (861) (989) (902) (965) (1,007) (1,149) (1,126) (1,129) (984) (1,208) (1,172) (986) (1,082) (1,514) (1,516) (668) (986)
Purchase of Seagen Inc. common stock (1,000)
Purchases of securities and other investments (455) (49) (15) (251) (117) (25) (562) (494) (5) (333) (372) (1) (17) (1) (28) (49)
Proceeds from sale of Seagen Inc. common stock 1,145
Proceeds from sales of securities and other investments 7 50 60 260 169 704 285 500 12 335 373 1 529 111 386 918 2 76 1,816
Acquisition of Eyebiotech Limited, net of cash acquired (1,344)
Acquisition of Elanco Animal Health Incorporated aqua business (2) (1,301)
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired (746)
Acquisition of MK-1045 (formerly CN201) from Curon Pharmaceutical (700)
Acquisition of Prometheus Biosciences, Inc., net of cash acquired (10,705)
Acquisition of Imago BioSciences, Inc., net of cash acquired (1,327)
Acquisition of Acceleron Pharma Inc., net of cash acquired (11,174)
Acquisition of Pandion Therapeutics, Inc., net of cash acquired (1,554)
Acquisition of VelosBio Inc., net of cash acquired (2,696)
Acquisition of ArQule, Inc., net of cash acquired (2,545)
Other (57) 233 (289) (14) (21) (19) (33) 37 (117) (166) 12 182 (196) (85) 11 (469) (640) (262) 136
Net cash used in investing activities (1,444) (3,845) (1,069) (1,376) 53 (334) (11,443) (2,359) (1,748) (962) (1,077) (1,173) (12,049) (1,061) (2,625) (686) (4,778) (2,155) (882) (1,628)
Net change in short-term borrowings (1,937) 1,937 (3) (4,771) 788 2,860 (2,278) (1,616) 3,583
Proceeds from issuance of debt (1) 3,600 (7) 5,946 7,936 (26) 4,445
Payments on debt (539) (751) (3) (1) (1,750) (1) (1) (1,000) (1,250) (1,166) (1,153) (3) (2) (1) (1,951)
Dividends paid to stockholders (1,951) (1,953) (1,986) (1,950) (1,852) (1,855) (1,885) (1,853) (1,750) (1,747) (1,770) (1,745) (1,643) (1,649) (1,673) (1,645) (1,542) (1,545) (1,577) (1,551)
Distribution from Organon & Co. 9,000
Purchases of treasury stock (489) (444) (251) (122) (393) (466) (338) (149) (18) (583) (239) (1,281)
Proceeds from exercise of stock options 12 5 73 87 6 7 82 30 265 10 97 12 134 17 42 9 21 28 14 26
Other (42) (32) (220) (78) (3) (10) (234) (81) (68) 35 (104) (103) (33) (59) (97) (97) 36 (28) (128) (316)
Net cash provided by (used in) financing activities (3,009) (2,425) 1,216 (2,814) (2,245) (4,269) 3,758 (2,054) (1,554) (2,702) (1,777) (3,086) 5,207 (2,274) 2,262 (2,098) 1,372 (3,851) 1,137 (1,490)
Net cash provided by operating activities (64) 500 551
Net cash used in investing activities (82) (52)
Net cash used in financing activities (504)
Net cash flows provided by discontinued operations (64) (86) 499
Effect of exchange rate changes on cash, cash equivalents and restricted cash (367) 294 (82) (138) 186 (157) (93) 87 366 (412) (309) (55) (68) (46) 78 (97) 164 87 65 (63)
Net increase (decrease) in cash, cash equivalents and restricted cash (1,370) 3,315 5,702 (1,238) (1,760) 2,957 (4,074) (2,987) 1,494 1,526 1,139 447 (1,879) 1,416 1,619 (1,142) 764 (3,746) 3,687 (2,474)

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Merck & Co. Inc. net cash provided by operating activities increased from Q2 2024 to Q3 2024 but then decreased significantly from Q3 2024 to Q4 2024.
Net cash used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Merck & Co. Inc. net cash used in investing activities decreased from Q2 2024 to Q3 2024 but then increased from Q3 2024 to Q4 2024 not reaching Q2 2024 level.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Merck & Co. Inc. net cash provided by (used in) financing activities decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.